As of 2026-03-29, the EV/EBITDA ratio of BioCryst Pharmaceuticals Inc (BCRX) is 7.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BCRX's latest enterprise value is 2,718.67 mil USD. BCRX's TTM EBITDA according to its financial statements is 354.47 mil USD. Dividing these 2 quantities gives us the above BCRX EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.0x - 15.6x | 14.0x |
| Forward P/E multiples | 14.4x - 18.2x | 16.5x |
| Fair Price | 15.48 - 24.13 | 20.01 |
| Upside | 65.9% - 158.6% | 114.4% |
| Date | EV/EBITDA |
| 2026-03-27 | 7.70 |
| 2026-03-26 | 7.83 |
| 2026-03-25 | 7.72 |
| 2026-03-24 | 7.90 |
| 2026-03-23 | 8.00 |
| 2026-03-20 | 7.93 |
| 2026-03-19 | 8.01 |
| 2026-03-18 | 7.55 |
| 2026-03-17 | 7.58 |
| 2026-03-16 | 7.65 |
| 2026-03-13 | 6.88 |
| 2026-03-12 | 7.00 |
| 2026-03-11 | 7.08 |
| 2026-03-10 | 7.26 |
| 2026-03-09 | 7.17 |
| 2026-03-06 | 7.07 |
| 2026-03-05 | 7.08 |
| 2026-03-04 | 7.13 |
| 2026-03-03 | 7.22 |
| 2026-03-02 | 7.17 |
| 2026-02-27 | 7.26 |
| 2026-02-26 | 6.66 |
| 2026-02-25 | 6.41 |
| 2026-02-24 | 6.45 |
| 2026-02-23 | 6.43 |
| 2026-02-20 | 6.34 |
| 2026-02-19 | 6.36 |
| 2026-02-18 | 6.21 |
| 2026-02-17 | 5.99 |
| 2026-02-13 | 5.85 |
| 2026-02-12 | 5.88 |
| 2026-02-11 | 5.91 |
| 2026-02-10 | 5.70 |
| 2026-02-09 | 5.53 |
| 2026-02-06 | 5.58 |
| 2026-02-05 | 5.48 |
| 2026-02-04 | 5.61 |
| 2026-02-03 | 5.81 |
| 2026-02-02 | 5.76 |
| 2026-01-30 | 5.72 |
| 2026-01-29 | 5.79 |
| 2026-01-28 | 5.78 |
| 2026-01-27 | 5.85 |
| 2026-01-26 | 5.92 |
| 2026-01-23 | 5.87 |
| 2026-01-22 | 5.84 |
| 2026-01-21 | 5.82 |
| 2026-01-20 | 5.79 |
| 2026-01-16 | 5.78 |
| 2026-01-15 | 6.14 |